ABSTRACT
Congenital diaphragmatic hernia (CDH) is a relatively common and genetically heterogeneous structural birth defect associated with high mortality and morbidity. We describe eight unrelated families with a novel X-linked condition characterized by diaphragm defects, variable anterior body wall anomalies, and/or facial dysmorphism. Using linkage analysis and whole exome or whole genome sequencing, we identified novel missense variants in the actin binding domains of plastin 3 (PLS3), a gene encoding an actin bundling protein, that co-segregate with disease in all families. Loss-of-function variants in PLS3 have been described previously in association with X-linked osteoporosis. To address these seemingly disparate clinical phenotypes, we performed in silico protein modeling and cellular overexpression experiments, which suggest that the affected residues in individuals with CDH are important for actin binding and result in disorganization of the actin cytoskeleton and a reduction in normal actin stress fiber formation. A mouse knock-in model of a variant identified in one of the families, p.W499C, shows partial perinatal lethality and recapitulates the key findings of the human phenotype, including diaphragm and abdominal wall defects. Both the mouse model and one surviving adult patient with a PLS3 variant were observed to have increased, rather than decreased, bone mineral density. Together, these clinical and functional data in human and mouse reveal that specific missense variants affecting the actin binding domains of PLS3 may have a gain-of-function effect and cause a new Mendelian disorder.
Competing Interest Statement
J.R.L. has stock ownership in 23andMe, is a paid consultant for Regeneron Genetics Center, and is a co-inventor on multiple United States and European patents related to molecular diagnostics for inherited neuropathies, eye diseases, and bacterial genomic fingerprinting. The Department of Molecular and Human Genetics at Baylor College of Medicine receives revenue from clinical genetic testing conducted at Baylor Genetics (BG) Laboratories; JRL is a member of the Scientific Advisory Board of BG. Other authors have no potential conflicts to report.
Funding Statement
The study was funded by grants from the National Institute of Child Health and Human Development (NICHD/NIH, http://www.nichd.nih.gov) 2P01HD068250 (P.K. Donahoe), R01 HD057036 (W. Chung), and RO1 HD098458 (D. Scott), the National Human Genome Research Institute (NHGRI) and the National Heart Lung and Blood Institute (NHBLI) to the Baylor-Hopkins Center for Mendelian Genomics (BHCMG, UM1 HG006542, J.R. Lupski). Sequencing services were partially provided through the RS&G Service by the Northwest Genomics Center at the University of Washington, Department of Genome Sciences, under U.S. Federal Government contract number HHSN268201100037C from the National Heart, Lung, and Blood Institute (M. Longoni, PI), and from the Gabriella Miller Kids First Pediatric Research Program X01 HL132366, X01 HL136998, and X01 HL140543 (W. Chung, PI).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study participants were recruited and provided written informed consent according to clinical investigation standards of the Partners/Mass General Brigham Human Research Committee, Boston Childrens Hospital Institutional Review Board, Columbia University Irving Medical Center (CUIMC) Institutional Review Board (IRB), and the Baylor College of Medicine Institutional Review Board. All IRB protocols were approved.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
WES data from families 2-4 has been deposited into the NIH National Center for Biotechnology Information (NCBI) Database of Genome and Phenotypes (dbGAP). WES data from families 7 and 8 will be deposited into NHGRI Genomic Data Science Analysis, Visualization, and Informatics Lab-space (AnVIL). WGS data for families 5 and 6 will be deposited into the data repository of the NICHD Gabriella Miller Kids First (GMKF) Program.
